Send the following on WhatsApp
Continue to Chathttps://it.marketscreener.com/quotazioni/azione/ALPHAMAB-ONCOLOGY-103501724/attualita/Alphamab-Oncology-annuncia-che-i-risultati-dello-studio-clinico-di-fase-II-di-KN046-in-combinazione-45898207/?utm_source=whatsapp&utm_medium=social&utm_campaign=share